6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Dated June 22, 2017

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant’s Name)

#1203-4464 Markham Street

Victoria, British Columbia

V8Z7X8

(250) 708-4272

(Address and telephone number of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☐            Form 40-F  ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):  ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☒             No  ☐

This Form 6-K is hereby filed and incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-206994).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 22, 2017.

Aurinia Pharmaceuticals Inc.
By:	/s/ Dennis Bourgeault
	Name: Dennis Bourgeault
	Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	News Release – Aurinia Announces Results of Annual General Meeting
99.2	Report on Voting Results

Exhibits 99.1 and 99.2 included with this report on Form 6-K are hereby incorporated by reference as an exhibit to the Registrant’s Registration Statement on Form F-10 (File No. 333-206994), as amended or supplemented.

3

EX-99.1

Exhibit 99.1

Aurinia Announces Results of Annual General Meeting

VICTORIA, British Columbia--(BUSINESS WIRE)--June 22, 2017--Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the six incumbent directors of the Company were elected at the Company’s annual general meeting held on June 21, 2017 (the “Meeting”).

Detailed results of the vote by proxy for the election of directors are provided below:

	Votes For (%)	Votes Withheld (%)
Nominee
Election of Directors
Richard Glickman	96.70%	3.30%
Benjamin Rovinski	99.09%	0.91%
David Jayne	71.78%	28.22%
Hyuek Joon Lee	98.95%	1.05%
Lorin Randall	75.43%	24.57%
George Milne	99.11%	0.89%

Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Aurinia

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company is currently developing voclosporin, an investigational drug, for the treatment of LN. The Company is headquartered in Victoria, BC and focuses its development efforts globally.

We seek Safe Harbor.

CONTACT:
Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia Economides
Vice President, Public Affairs
ceconomides@auriniapharma.com

EX-99.2

Exhibit 99.2

AURINIA PHARMACEUTICALS INC.

Report of Voting Results

This report is filed pursuant to Section 11.3 of National Instrument 51-102 and relates to the results of voting at the annual general meeting of Aurinia Pharmaceuticals Inc. (the “Company”) held on June 21, 2017.

Description of Matter

Resolution to elect the management nominees as directors of the Company.

Resolution to appoint

PricewaterhouseCoopers LLP, Chartered Professional Accountants as auditors of the Company until its next annual general meeting, at a remuneration to be fixed by the directors.

Resolution to approve the unallocated entitlements under the Company's stock option plan

Outcome of Vote

All nominees proposed by management were elected to serve as directors of the Company until its next annual general meeting.

Details of the voting by proxy are as follows:

Name	Votes in Favour	Votes Withheld
Richard Glickman	25,669,594 (96.70%)	875,695 (3.30%)
Benjamin Rovinski	26,302,828 (99.09%)	242,461 (0.91%)
David Jayne	19,053,026 (71.78%)	7,492,263 (28.22%)
Hyuek Joon Lee	26,266,015 (98.95%)	279,274 (1.05%)
Lorin Randall	20,022,046 (75.43%)	6,523,243 (24.57%)
George Milne	26,308,565 (99.11%)	236,724 (0.89%)

Resolution passed by requisite majority.

Details of the voting by proxy are as follows:

Total shares voted in favour: 62,311,503 (98.69%)

Total shares withheld: 825,361 (1.31%)

Resolution passed by requisite majority.

Details of the voting by ballot are as follows:

Total shares voted in favour: 18,788,103 (70.23%)

Total shares voted against: 7,965,988 (29.77%)

DATED this 22^nd day of June, 2017

AURINIA PHARMACEUTICALS INC.

By:	/s/ Dennis Bourgeault
	Name:  Dennis Bourgeault
	Title:    Chief Financial Officer

- 2 -